Brokerages Set Repligen Co. (NASDAQ:RGEN) Price Target at $208.56

Shares of Repligen Co. (NASDAQ:RGEN – Get Rating) have been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $208.56.

Several research firms recently issued reports on RGEN. Benchmark dropped their price target on shares of Repligen from $230.00 to $210.00 in a research note on Wednesday, May 3rd. Stifel Nicolaus dropped their price target on shares of Repligen from $225.00 to $210.00 in a research note on Wednesday, May 3rd. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Repligen from $180.00 to $165.00 in a research note on Wednesday, May 3rd. StockNews.com assumed coverage on shares of Repligen in a research note on Thursday, May 18th. They set a “sell” rating on the stock. Finally, TheStreet lowered shares of Repligen from a “b-” rating to a “c+” rating in a report on Monday, May 8th.

Insider Activity

In other Repligen news, Director Martin D. Madaus purchased 500 shares of the firm’s stock in a transaction dated Monday, May 8th. The stock was acquired at an average cost of $156.18 per share, with a total value of $78,090.00. Following the acquisition, the director now owns 1,611 shares of the company’s stock, valued at approximately $251,605.98. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 1.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RGEN. Hanseatic Management Services Inc. acquired a new position in Repligen during the 3rd quarter valued at about $27,000. BI Asset Management Fondsmaeglerselskab A S boosted its stake in Repligen by 120.0% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 209 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 114 shares during the period. Fortis Capital Advisors LLC bought a new stake in shares of Repligen during the 4th quarter worth about $35,000. Clearstead Advisors LLC bought a new stake in shares of Repligen during the 1st quarter worth about $38,000. Finally, Whittier Trust Co. raised its position in shares of Repligen by 108.6% during the 1st quarter. Whittier Trust Co. now owns 242 shares of the biotechnology company’s stock worth $41,000 after buying an additional 126 shares in the last quarter. 91.00% of the stock is owned by institutional investors and hedge funds.

Repligen Trading Up 1.6 %

Shares of RGEN stock opened at $167.86 on Tuesday. The company’s fifty day simple moving average is $163.15 and its 200-day simple moving average is $172.98. Repligen has a 52 week low of $137.65 and a 52 week high of $262.26. The company has a market cap of $9.35 billion, a PE ratio of 56.90, a P/E/G ratio of 3.00 and a beta of 1.08.

Repligen (NASDAQ:RGEN – Get Rating) last issued its earnings results on Tuesday, May 2nd. The biotechnology company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.59 by $0.05. Repligen had a net margin of 21.58% and a return on equity of 9.14%. The business had revenue of $182.70 million for the quarter, compared to the consensus estimate of $181.43 million. During the same quarter last year, the firm posted $0.92 EPS. The business’s revenue for the quarter was down 11.5% compared to the same quarter last year. Equities research analysts expect that Repligen will post 2.37 EPS for the current fiscal year.

About Repligen

(Get Rating)

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G.